Leading clinician and researcher in Pulmonary Disease TherapeuticsNEW HAVEN, Conn., Feb. 19, 2025 (GLOBE NEWSWIRE) -- OrphAI Therapeutics Inc. (“OrphAI”), a clinical-stage biopharmaceutical company ...

The following is a summary of “Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with ...

A mom who takes nothing for granted is sharing her story after almost dying from a pulmonary embolism during childbirth.

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

Pulmonary hypertension is a common complication of systemic sclerosis and generally portends a very poor prognosis. Response to modern therapy for scleroderma-related pulmonary arterial ...

A mom who takes nothing for granted is sharing her story after almost dying from a pulmonary embolism during childbirth. Aaliyah Walker cherishes the simple moments, from holding her babies in her ...

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause ...

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

The results suggest that early diagnosis and sustained control ... This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading ...